Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration

Objective: Assess the efficacy of intravitreal aflibercept on pigment epithelial detachments (RED) associated with previously treated patients with neovascular age-related macular degeneration (AMD). Design: Retrospective study. Participants: Sixty eyes. Methods: Patients with persistent RED who were treated with intravitreal aflibercept (2.0 mg) with >2 previous injections of bevacizumab (1.25 mg) or ranibizumab (0.5 mg) were analyzed. Results: Mean number of prior injections was 24.8 during a mean of 32 months of management (range 3-77 months). Baseline mean FED height was 258 mu m (range 80-687 mu m), which decreased at 1, 6, and 12 months upon switching to aflibercept to 226 pm (-14%, range 34-701 mu m), 215 pm (-18%, range 0-666 mu m), and 208 mu m (-22%, range 0-752 pm), respectively. The majority of eyes experienced a decrease in FED height after switching to aflibercept: 50/58 (86%), 38/47 (81%), and 37/47 (79%) at months 1, 6, and 12, respectively. Reduction in FED height was weakly correlated with improved visual acuity (R-2 = 0.11). Conclusions: Intravitreal aflibercept resulted in significant reduction in FED height in previously treated eyes with neovascular AMD.